Enliven Therapeutics is a clinical-stage concern that has two candidates in its pipeline targeting oncology indications.

Millions of individuals rely on effective medications to manage diseases like cancer and diabetes. For those with chronic myeloid leukemia (CML), advancements in treatment selection could ...

Ascentage Pharma (AAPG) announced that two of its proprietary novel drugs have been included in the 2025 Chinese Society of Clinical Oncology, ...

Researchers have explored the evolution of the genetic change that causes chronic myeloid leukaemia and show its ability to drive the disease.

3). Such compounds may potentially be unaffected by mutations of the kinase domain that make BCR–ABL1-positive leukaemic cells resistant to imatinib. Figure 3: Different modes of BCR–ABL binding.

It occurs when pieces of chromosomes 9 and 22 switch with each other to form abnormal structures and the development of the BCR-ABL1 kinase, which is targeted by Iclusig. The accelerated approval ...

BCR and ABL1, become abnormally joined together. With targeted therapy using tyrosine kinase inhibitors (TKIs), patients with CML may achieve deep molecular responses. Patients who reach this ...